Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation

Stem Cells
L von BahrK Le Blanc

Abstract

Mesenchymal stromal cells (MSCs) are explored as a novel treatment for a variety of medical conditions. Their fate after infusion is unclear, and long-term safety regarding malignant transformation and ectopic tissue formation has not been addressed in patients. We examined autopsy material from 18 patients who had received human leukocyte antigen (HLA)-mismatched MSCs, and 108 tissue samples from 15 patients were examined by PCR. No signs of ectopic tissue formation or malignant tumors of MSC-donor origin were found on macroscopic or histological examination. MSC donor DNA was detected in one or several tissues including lungs, lymph nodes, and intestine in eight patients at levels from 1/100 to <1/1,000. Detection of MSC donor DNA was negatively correlated with time from infusion to sample collection, as DNA was detected from nine of 13 MSC infusions given within 50 days before sampling but from only two of eight infusions given earlier. There was no correlation between MSC engraftment and treatment response. We conclude that MSCs appear to mediate their function through a "hit and run" mechanism. The lack of sustained engraftment limits the long-term risks of MSC therapy.

References

Feb 28, 2003·Proceedings of the National Academy of Sciences of the United States of America·Jeffrey L SpeesDarwin J Prockop
Oct 21, 2005·Cytotherapy·E M HorwitzUNKNOWN International Society for Cellular Therapy
Oct 14, 2006·Stem Cells·Jakub TolarBruce R Blazar
May 13, 2008·Lancet·Katarina Le BlancUNKNOWN Developmental Committee of the European Group for Blood and Marrow Transplantation
Jun 30, 2009·Journal of Immunotherapy·Mikael SundinKatarina Le Blanc
Dec 25, 2009·Blood·Karin TarteUNKNOWN Société Française de Greffe de Moelle et Thérapie Cellulaire
Aug 26, 2010·Cytotherapy·Darwin J ProckopArmand Keating

❮ Previous
Next ❯

Citations

Jun 29, 2012·Stem Cells and Development·Dimitrios MougiakakosKatarina Le Blanc
Aug 27, 2013·Endocrine-related Cancer·W Nathaniel BrennenJohn T Isaacs
Dec 1, 2012·Stem Cells Translational Medicine·Ruth S WatermanAline M Betancourt
Dec 1, 2012·Stem Cells Translational Medicine·Krisztina Szöke, Jan E Brinchmann
Jul 17, 2013·American Journal of Respiratory and Critical Care Medicine·Daniel J Weiss, Luis A Ortiz
Nov 13, 2013·Nature Reviews. Rheumatology·Alan Tyndall
Feb 25, 2014·Nature Biotechnology·James A AnkrumJeffrey M Karp
Jan 1, 2014·Current Opinion in Rheumatology·Kenneth F Baker, John D Isaacs
Jan 12, 2013·American Journal of Respiratory and Critical Care Medicine·Rebecca L ToonkelMarilyn K Glassberg
Nov 28, 2013·Current Opinion in Organ Transplantation·Martin J HoogduijnCarla C Baan
Aug 8, 2014·Stem Cell Research & Therapy·Luke WatsonCynthia M Coleman
Sep 11, 2012·Biotechnology Advances·Ruenn Chai LaiSai Kiang Lim
Aug 26, 2014·Annual Review of Cell and Developmental Biology·Paolo Bianco
Jan 5, 2016·Best Practice & Research. Clinical Obstetrics & Gynaecology·Cecilia Götherström
Nov 11, 2015·Human Reproduction Update·Caroline E GargettJames A Deane
Mar 25, 2014·Expert Opinion on Drug Discovery·Fernando E FigueroaAntonio La Cava
Dec 15, 2015·International Journal of Hematology·Nayoun Kim, Seok-Goo Cho
Jun 5, 2013·Chest·Jeffrey E Gotts, Michael A Matthay
Nov 23, 2012·Chest·Daniel J WeissDonald P Tashkin
Jan 13, 2016·Stem Cell Research & Therapy·Johannes Leibacher, Reinhard Henschler
Jun 16, 2015·Immunology Letters·Wei CaoYufang Shi
Jun 21, 2015·Immunology Letters·C CapelliM Introna
Jun 8, 2013·Stem Cells·Sami PalomäkiPeppi Koivunen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.